ALK and non-small cell lung carcinoma: In particular, the introduction of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has transformed the treatment possibilities for patients with advanced NSCLC, with ALK gene rearrangements, affording an objective response rate of 74% and prolonged survival (3, 4).